- Home
- RYET vs SCPH Comparison
RYET vs SCPH Comparison
Compare RYET & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYET
- SCPH
- Stock Information
- Founded
- RYET 2012
- SCPH 2013
- Country
- RYET China
- SCPH United States
- Employees
- RYET N/A
- SCPH N/A
- Industry
- RYET
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- RYET
- SCPH Health Care
- Exchange
- RYET NYSE
- SCPH Nasdaq
- Market Cap
- RYET 206.2M
- SCPH 173.6M
- IPO Year
- RYET 2025
- SCPH 2017
- Fundamental
- Price
- RYET $12.58
- SCPH $3.64
- Analyst Decision
- RYET
- SCPH Strong Buy
- Analyst Count
- RYET 0
- SCPH 3
- Target Price
- RYET N/A
- SCPH $14.00
- AVG Volume (30 Days)
- RYET 1.3M
- SCPH 423.8K
- Earning Date
- RYET 01-01-0001
- SCPH 05-14-2025
- Dividend Yield
- RYET N/A
- SCPH N/A
- EPS Growth
- RYET N/A
- SCPH N/A
- EPS
- RYET N/A
- SCPH N/A
- Revenue
- RYET $6,989,985.00
- SCPH $41,982,000.00
- Revenue This Year
- RYET N/A
- SCPH $109.32
- Revenue Next Year
- RYET N/A
- SCPH $76.95
- P/E Ratio
- RYET N/A
- SCPH N/A
- Revenue Growth
- RYET N/A
- SCPH 138.10
- 52 Week Low
- RYET $2.68
- SCPH $1.94
- 52 Week High
- RYET $15.30
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- RYET N/A
- SCPH 66.63
- Support Level
- RYET N/A
- SCPH $3.23
- Resistance Level
- RYET N/A
- SCPH $3.74
- Average True Range (ATR)
- RYET 0.00
- SCPH 0.31
- MACD
- RYET 0.00
- SCPH 0.08
- Stochastic Oscillator
- RYET 0.00
- SCPH 93.81
About RYET RUANYUN EDAI TECHNOLOGY INC
Ruanyun Edai Technology Inc is primarily engaged in providing online academic exercise question banks with A.I. capabilities, online classes and homework, and on-demand lectures and evaluations that cover all K-12 subject fields and grade levels.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.